<DOC>
	<DOCNO>NCT00090675</DOCNO>
	<brief_summary>In Phase IIIb , randomize , double-blind , maintenance study , 300 subject advanced metastatic Non-Small Cell Lung Cancer ( NSCLC ) ( Stage IIIB { T4-pleural effusion } IV ) SD objective tumor response immediately follow completion 4-6 cycle front line , platinum-based , doublet chemotherapy randomize double-blind manner receive either ZD1839 placebo .</brief_summary>
	<brief_title>Maintenance ZD1839 ( IRESSA® ) Following Completion Front Line , Platinum-Based , Double Chemotherapy Subjects With Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Must sign Informed Consent Females male age 18 year . Confirmed stage IIIB ( T4pleural effusion ) IV NSCLC . Either complete response , partial response , stable disease follow least 4 cycle ( 3 set intolerable toxicity ) 6 cycle definitive front line , platinumbased , doublet chemotherapy . No prior EGFR therapy No newly diagnose intracerebral metastasis receive complete chemotherapy At least 3 week ( 21 day ) 4 week ( 28 day ) since last dose chemotherapy Must completely heal previous major oncologic surgery Life expectancy ≥ 8 week . Known severe hypersensitivity ZD1839 excipients product . Any evidence clinically active interstitial lung disease ( subject chronic , stable , radiographic change asymptomatic need exclude ) . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ . Any unresolved chronic toxicity great common toxicity criterion ( CTC ) grade 2 previous anticancer therapy exclude peripheral neuropathy alopecia . Evidence significant clinical disorder laboratory find make undesirable subject participate study . Pregnancy breast feeding ( woman child bear potential ) . Women childbearing potential must practice acceptable method birth control prevent pregnancy . Treatment nonapproved investigational drug within 30 day Day 1 study treatment . Signs neurological symptom consistent new onset spinal cord compression CNS metastases . Treatment systemic anticancer therapy prescribe protocol chemotherapy regimen ( refer Inclusion criterion ) . Exception : Palliative radiotherapy symptom relief lesion present diagnosis allow ; however , radiotherapy must occur prior completion prestudy doublet chemotherapy . Males must also willing practice acceptable method birth control take drug prevent pregnancy partner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>